Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Lu, Jingwei ^a   Aggarwal, Reeva ^a   Kanji, Suman ^a   Das, Manjusri ^a   Joseph, Matthew ^a   Pompili, Vincent ^a   Das, Hiranmoy ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROPIDIUM IODIDE; PROTEIN MICA; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; MAPK1 PROTEIN, HUMAN; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CELL CONTACT; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; OVARY TUMOR; TUMOR CELL DESTRUCTION; TUMOR ESCAPE; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL COMMUNICATION; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

APOPTOSIS; CELL COMMUNICATION; CELL CYCLE; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVARIAN NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; UP-REGULATION;

EID: 80052832382     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023348     Document Type: Article

References (48)

1. Porcelli S, Brenner MB, Band H, (1991) Biology of the human gamma delta T-cell receptor. Immunol Rev 120: 137-183.
2. Morita CT, Parker CM, Brenner MB, Band H, (1994) TCR usage and functional capabilities of human gamma delta T cells at birth. J Immunol 153: 3979-3988.
3. Hara T, Mizuno Y, Takaki K, Takada H, Akeda H, et al. (1992) Predominant activation and expansion of V gamma 9-bearing gamma delta T cells in vivo as well as in vitro in Salmonella infection. J Clin Invest 90: 204-210.
4. Bukowski JF, Morita CT, Brenner MB, (1999) Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11: 57-65.
5. Morita CT, Jin CG, Sarikonda G, Wang H, (2007) Nonpeptide antigens, presentation mechanisms, and immunological memory of human V gamma 2 V delta 2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunological Reviews 215: 59-76.
6. Kyriazi S, Kaye SB, deSouza NM, (2010) Imaging ovarian cancer and peritoneal metastases-current and emerging techniques. Nat Rev Clin Oncol 7: 381-393.
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
9. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.
10. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, et al. (2005) Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 16: 590-596.
11. Wu J, Groh V, Spies T, (2002) T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 169: 1236-1240.
12. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, et al. (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6: 928-937.
13. Eleme K, Taner SB, Onfelt B, Collinson LM, McCann FE, et al. (2004) Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. Journal of Experimental Medicine 199: 1005-1010.
14. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96: 6879-6884.
15. Champsaur M, Lanier LL, (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267-285.
16. Groh V, Wu J, Yee C, Spies T, (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
17. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, et al. (2007) Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
18. Salih HR, Rammensee HG, Steinle A, (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102.
19. Das H, Groh V, Kuijl C, Sugita M, Morita CT, et al. (2001) MICA engagement by human V gamma 2 V delta 2 T cells enhances their antigen-dependent effector function. Immunity 15: 83-93.
20. Das H, Wang L, Kamath A, Bukowski JF, (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98: 1616-1618.
21. Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, et al. (2003) Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 18: 355-365.
22. Vermijlen D, Froelich CJ, Luo DZ, Suarez-Huerta N, Robaye B, et al. (2001) Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. Cancer Immunology Immunotherapy 50: 212-217.
23. Yazlovitskaya EM, DeHaan RD, Persons DL, (2001) Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochemical and Biophysical Research Communications 283: 732-737.
24. Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, et al. (2003) MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Research 63: 8996-9006.
25. Sapino A, Bongiovanni M, Cassoni P, Righi L, Arisio R, et al. (2001) Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. Journal of Pathology 194: 254-261.
26. Hutchins D, Steel CM, (1994) Regulation of Icam-1 (Cd54) Expression in Human Breast-Cancer Cell-Lines by Interleukin-6 and Fibroblast-Derived Factors. International Journal of Cancer 58: 80-84.
27. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, et al. (2003) Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Research 63: 2278-2283.
28. Xu G, Chakraborty C, Lala PK, (2001) Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun 287: 47-55.
29. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR, (2005) Activation of AKT kinases in cancer: Implications for therapeutic targeting. Advances in Cancer Research Vol 94 94: 29-+.
30. Syed V, Ulinski G, Mok SC, Ho SM, (2002) Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. Journal of the National Cancer Institute 94: 617-629.
31. Fang L, Li GN, Liu GZ, Lee SW, Aaronson SA, (2001) p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. Embo Journal 20: 1931-1939.
32. DeHaan RD, Yazlovitskaya EM, Persons DL, (2001) Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemotherapy and Pharmacology 48: 383-388.
33. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791.
34. Russell RG, Rogers MJ, (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25: 97-106.
35. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, et al. (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392.
36. Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
37. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
38. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, et al. (2003) Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22: 8653-8661.
39. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, et al. (2000) Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 191: 937-948.
40. Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, et al. (1997) P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 385: 81-83.
41. Roth SJ, Diacovo TG, Brenner MB, Rosat JP, Buccola J, et al. (1998) Transendothelial chemotaxis of human alpha/beta and gamma/delta T lymphocytes to chemokines. Eur J Immunol 28: 104-113.
42. Pietenpol JA, Stewart ZA, (2002) Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 181-182: 475-481.
43. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
44. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, et al. (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109: 720-728.
45. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB, (1998) Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci U S A 95: 11107-11112.
46. Tang D, Wu D, Hirao A, Lahti JM, Liu L, et al. (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717.
47. Das H, Sugita M, Brenner MB, (2004) Mechanisms of Vdelta1 gammadelta T cell activation by microbial components. J Immunol 172: 6578-6586.
48. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, et al. (2009) Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 329: 543-550.